mesothelioma cancer Rosetta Genomics Partners With NYU Medical Center to Develop a Line of Diagnostic Tools for Lung and Mesothelioma Cancers mesothelioma asbestos mesothelioma lung cancer mesothelioma symptoms |

Latest Data

Updated New Hpv-dna Test To Screen Women In Developing Countries For Cervical Precancerous Disease Has 90% Success Rate
Update Hollings Cancer Center Creates $1 Million Endowed Chair For Breast Cancer Research And Treatment With Gift From The Spaulding-paolozzi Foundation
Updated Statins Don't Cause Cancer, Study Finds (reuters)
Subject Greater Gains In Mortality Reduction From Common Cancers Associated With Higher Education
Update New Genetic Techniques To Combat Lung Cancer
Update Morphine: A Comfort Measure For The Dying Or Pain Control For The Living?
New Entry Tobacco Companies In Recent Years Adjusted Menthol Levels In Different Brands Of Cigarettes To Attract Younger Smokers, Study Finds
Comments Requested Graveyard Shift Work Linked To Cancer (ap)
Comments Requested Australian Disease Research Boosted By National Alliance
Important Bevacizumab Found To Improve Survival For Patients With Advanced Breast Cancer

Search

Mesothelioma

Rosetta Genomics Partners With NYU Medical Center to Develop a Line of Diagnostic Tools for Lung and Mesothelioma Cancers

By admin | September 13, 2007

Rosetta Genomics, Ltd. announced that it has partnered with NYU Medical Center with the aim of developing a line of early detection diagnostic products for lung, and Mesothelioma cancers.

The early detection test will mainly target over 45 million Americans who are at an increased risk of lung cancer due to smoking, as well as those who have been exposed to asbestos fibers. The test will utilize Rosetta Genomics’ proprietary protocol to extract microRNAs from a simple blood draw.

“A test that will be able to detect cancer at an early stage using a simple blood draw will have far reaching implications on the fight against cancer,” noted Dr. Harvey Pass, Professor and Chief, Division of Thoracic Surgery and Thoracic Oncology at NYU Medical Center. “MicroRNAs have been shown to hold great potential as effective biomarkers for various cancers, and I believe that NYU Medical Center’s vast experience with lung cancer and Mesothelioma, coupled with Rosetta Genomics’ expertise in the microRNA field, will allow us to successfully advance this much needed test forward.”

This entry was important to me: These icons link to social bookmarking sites where readers can share and discover new web pages.